Compare Mesoblast Limited (MESO) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SoFi Technologies Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while SoFi Technologies Inc trades at $17.15 (market cap $21.82B). The key difference: SoFi Technologies Inc is far larger — about 10.1× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| MESO | SOFI | |
|---|---|---|
Market Cap | $2.17B | $21.82B |
Sector | Technology | Financials |
52-Week High | $20.96 | $32.21 |
52-Week Low | $12.88 | $15.15 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SOFI Technologies trades at $17.07, down 1.22% with a bearish technical signal. The company shows strong revenue growth, reaching $3.61B in 2025 with consistent earnings beats, though net income declined to $481M. Analyst consensus is mixed with a $22.43 price target, while recent news highlights upcoming Q2 earnings and takeover speculation.
SOFI presents growth potential with 30% revenue guidance and digital platform expansion, but faces risks from negative operating cash flow and competitive pressures. The stock's current valuation at 38.4 P/E requires continued execution to justify upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
